Market Overview

Research and Markets: Hemophilia - Pipeline Review, H2 2012

Share:
DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vghl6z/hemophilia) has announced the addition of Global Markets Direct's new report "Hemophilia - Pipeline Review, H2 2012" to their offering.

This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia.

Scope

- A snapshot of the global therapeutic scenario for Hemophilia.

- A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hemophilia.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Hemophilia therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Involved in Hemophilia Therapeutics Development

- Baxter International Inc.

- Biogen Idec Inc.

- Nektar Therapeutics

- VIRxSYS Corporation

- Lentigen Corporation

- Sangamo BioSciences, Inc.

- Novo Nordisk A/S

- Dong-A Pharmaceutical Co., Ltd.

- GTC Biotherapeutics, Inc.

- Octapharma AG

- Pfizer Inc.

- Bayer AG

- PROLOR Biotech, Inc.

- ReGenX Biosciences, LLC

- PAION AG

- Alnylam Pharmaceuticals, Inc

- Flamel Technologies S.A.

- CSL Limited

- Recoly N.V.

- EpiVax, Inc.

- Inspiration Biopharmaceuticals, Inc.

- Discovery Genomics, Inc.

- Ascendis Pharma A/S

For more information visit http://www.researchandmarkets.com/research/vghl6z/hemophilia

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

View Comments and Join the Discussion!